Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.40) by 11.43 percent. This is a 55.23 percent increase over losses of $(2.77) per share from the same period last year. The company reported quarterly sales of $35.066 million which beat the analyst consensus estimate of $31.399 million by 11.68 percent. This is a 16.83 percent increase over sales of $30.015 million the same period last year.